Evidence map›Paper›PMID 34173094›Full record

Trial reportBulletin of experimental biology and medicine2021

The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.

O G Artamonova, A E Karamova, A A Nikonorov, D A Verbenko, E L Vasileva, A A Kubanov

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bulletin of experimental biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

O G ArtamonovaState Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia. artamonova_olga@list.ru.
A E KaramovaState Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia.
A A NikonorovState Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia.
D A VerbenkoState Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia.
E L VasilevaState Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia.
A A KubanovState Research Center for Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, Moscow, Russia.
State Research Center for Dermatovenereology and Cosmetology · RUMinistry of Health of the Russian Federation · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In patients with moderate-to-severe and severe psoriasis and high efficacy of therapy (PASI≥75) with signaling pathway inhibitors (apremilast, tofacitinib), cytokine spectra in the skin and blood plasma were studied using xMAP technology at baseline and on weeks 14 and 26 of treatment. Comparison of cytokine levels in psoriatic lesional skin and plasma samples of patients treated with apremilast or tofacitinib revealed statistical difference only for IFNγ level (р<0.05) at week 26.

Indexed as

AdultCohort StudiesCytokinesFemaleHumansJanus Kinase InhibitorsMaleMiddle AgedPhosphodiesterase 4 InhibitorsPiperidinesPsoriasisPyrimidinesSeverity of Illness IndexSkinThalidomideTreatment OutcomeapremilastCytokinesJanus Kinase InhibitorsPhosphodiesterase 4 InhibitorsPiperidinesPyrimidinesThalidomidetofacitinibapremilastJanus kinase inhibitorsphosphodiesterase-4 inhibitorpsoriasistofacitinib

Identifiers

PMID34173094
OpenAlexW3130798298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.